Separate names with a comma.
Price $1.13 ...Market cap $45 Million ...Cash $115Million ...Book Value $3.30 ...Cash per Share $2.79 = STRONG BUY UPCOMING BIG MILESTONES...
Looks like major breakout on the way [IMG]
NDA submission for Qtrypta approval and Partnership for the drug which means huge upfront payments still expected during this Quarter =MASSIVE...
What you get for the Market Cap of laughable $42 Million = you get $115 M of Cash or enough untill end 2021 / 2 Approved Drugs for which they own...
Book Value $3.30 / Cash per Share $2.79 / 2+ years of Cash / 2 Approved Drugs / Another one with strong phase 3 results /Licensing Deals + Eskata...
New presentation https://investor.aclaristx.com/static-files/64237ff2-0c1b-45f6-a306-d7d9cb8c700e
Market cap at ridiculous $29 Million / NDA Submission + Partnership which means UPFRONT payments expected during Q4 =MEGA POTENTIAL HERE Company...
With One Late-Stage Study Out Of The Way, Aclaris Moves One Inch Closer To Commercialization...
Looks like another jump to $2++ coming [IMG]
Eskata approval in Canada expected within 3 Weeks will trigger milestone payment to ACRS and will push stock much higher again .And there is more...
With $115 Million Cash or untill late 2021 and more Cash + Royalties from partnering of their commercial and pipeline assets (expected soon) and...
strong buy here trading still massive under cash
if your a shareholder please put a high gtc sell order in $5 or higher .thank you Q:What can you do to prevent your shares holdings from being...
great buying opp again here ,, more news coming shortly like partner deals and second phase 3 readout
next big leg up coming ,,,big news like partner deals and another phase 3 readout expected shortly
3-4 Weeks then drug approvals likely to come in .. this low float stock could double quickly.GL [IMG]
Exploding in pre mkt up 100% or $2.10 which is still below the $2.80 cash per share ..terrible underpriced
BOOOOOOOOOOOOOOOOOOOOOOOM and still trading below cash which alone is $2.80 per share
POSITIVEE PHASE 3 RESULTS YIPPIIIIIIIIIIIIIII Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy...
Major breakout to $2+ could starty anytime now wh [IMG]
